A novel gene signature associated with poor response to chemoradiotherapy in patients with locally advanced cervical cancer.

ABSTRACT:

Objective

We aimed to investigate the distinct transcriptional landscape in poor responders to concurrent chemoradiotherapy (CCRT) and to gain mechanistic insights into treatment resistance in cervical cancer.

Methods

RNA sequencing was performed in patients with locally advanced cervical cancer treated with platinum-based CCRT. Transcriptome data of no durable benefit (NDB; progression-free period <3 years) and durable clinical benefit (DCB; progression-free period >5 years) patients were compared. The NDB score was estimated for each patient using differentially expressed genes between NDB and DCB patients. The potential response to programmed death-1 blockade was estimated using the tumor immune dysfunction and exclusion (TIDE) score and T-cell-inflamed gene expression pr

SUBMITTER: Kim KH 

PROVIDER: S-EPMC8728662 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature